Shivan Sivakumar awarded 3-year Celgene Fellowship

Shivan Sivakumar is a clinician-scientist with an interest in pancreatic cancer who has been awarded a 3 year Celgene Fellowship. Following medical training at QMUL, a PhD at Cambridge supervised by David Tuveson and Kathryn Lilley, and a short post-doc with Florian Markowetz, Shivan completed his core medical training during  post-doc and clinical lecturer positions at Oxford. He divides his time between the Churchill Hospital, Department of Oncology, and Kennedy Institute of Rheumatology undertaking clinical work, clinical trials (Mark Middleton) and fundamental immunology research (Mike Dustin).

Pancreatic cancer has the worst prognosis of any cancer, with a 0% 5-year survival rate for those with metastatic disease. A number of issues are associated with poor prognosis- late diagnosis, an undruggable KRAS oncogene, and the pancreas’ deep-seated position which means only a small percentage of the tumour is made up of tumour tissue (with the rest being stroma, immune cells, and a desmoplastic reaction). Shivan’s work aims to establish novel treatment strategies by:

  • Evaluating the efficacy of therapeutic strategies by studying the biology and the effect of the drug on the tumour. Treatment strategies will be evaluated in a small number of patients before moving on to a larger trial.
  • Carrying out fundamental research to understand the tumour microenvironment of pancreatic cancer through a combination of immune monitoring and single cell genetic analysis. Shivan’s work in the past 4 years has centred on establishing an immune signature in pancreatic cancer and identifying particular T cells implicated in the disease. The next phase is to look at all the immune cells in an unbiased way.

In Oxford, Shivan collaborates with Enas Abu Shah (immunology, KIR), Rachel Bashford-Rogers (single-cell sequencing, WTCHG), Constantin Coussios (drug delivery, IBME), Len Seymour and Kerry Fisher (virotherapy, Oncology) Chunxiao Song (Early detection, Ludwig), and David Wedge (cancer evolution, BDI). Shivan’s work will be supported by the Celgene Translational Fellowship for the next three years, looking at the immune compartment of pancreatic cancer in an unbiased way. Since 2015, Shivan has also been funded by LAP, John Fell Fund, NIHR and CRUK

Find out more about our research below

Eoghan Mullholland awarded colorectal cancer fellowship

As part of UK Pride month, we are spotlighting the work of cancer researcher and University LGBTQ+ Representative Dr Eoghan Mulholland

New study investigates how growth factors in our gut could initiate cancer

Dr Francesco Boccellato is investigating the mechanisms of tissue regulation in the healthy stomach and in a pre-cancerous condition known as atrophic gastritis. This may help to identify those who may have cancer, as well as find new ways to prevent cancer from progressing

Understanding how cancer arises from infected tissue

Dr Francesco Boccellato is investigating the mechanisms behind the pre-cancerous condition known as atrophic gastritis. This may help to identify those who may have cancer, as well as find new ways to prevent cancer from progressing

Bowel cancer patients going undiagnosed due to COVID distruption

A new study led by the University of Oxford has found that since the first coronavirus lockdown the number of people diagnosed with bowel cancer in England has fallen sharply, with a deficit persisting up to October 2020

Bioengineering the human gut

An interdisciplinary collaboration generates an advanced model of the human gastrointestinal tract with broad applications for disease research and regenerative medicine
Image from an endoscopy video with the detected artefacts highlighted with coloured boxes.

Using AI to improve the quality of endoscopy videos

A multidisciplinary team of researchers has developed a deep-learning framework for improving endoscopy to aid cancer detection.

How chemotherapy impacts the body

A new study has investigated how chemotherapy impacts oesophageal cancer patients and if this determines a patient’s risk of post-operative complications

First Huaxi SCU-Oxford Forum on Gastrointestinal Cancer

The first Centre Forum was held in China this week, from 27-28th September 2020

Oxford University and Sichuan University form joint Centre for Gastrointestinal Cancer

The University of Oxford-Sichuan University Huaxi Joint Centre for Gastrointestinal Cancer is a new international collaboration that seeks to develop an integrated gastrointestinal cancer plan through the exchanging of ideas and resources.